Skip to content

Current ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.3×+0.1×
Janux Therapeutics logo
Janux TherapeuticsJANX
17×-41.5×
Allogene Therapeutics logo
Allogene TherapeuticsALLO
9.6×-0.1×
Vor Biopharma logo
Vor BiopharmaVOR
31.1×+27.3×
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
22.3×-6.1×

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×

Where this comes from

Calculated from CytomX Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's current ratio?
CytomX Therapeutics (CTMX) reported current ratio of 10.4× in Q1 2026.
How has CytomX Therapeutics's current ratio changed year-over-year?
CytomX Therapeutics's current ratio increased by 501.4% year-over-year, from 1.7× to 10.4×.
What is the long-term trend for CytomX Therapeutics's current ratio?
Over 5 years (2020 to 2025), CytomX Therapeutics's current ratio has grown at a -8.3% compound annual growth rate (CAGR), from 4.8× to 3.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.